Prevalence of axial spondyloarthritis in Poland

Tłustochowicz, Małgorzata; Brzozowska, Melania; Wierzba, Waldemar; Raciborski, Filip; Kwiatkowska, Brygida; Tłustochowicz, Witold; Jacyna, Andrzej; Marczak, Michał; Kisiel, Bartłomiej; Śliwczyński, Andrzej

doi:10.1007/s00296-019-04482-7

Cited by 6 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As for the associations of IL-17 polymorphisms with other diseases, many previous studies focused on 4 Mediators of Inflammation GG vs. GA+AA, p = 0:005; 5 Mediators of Inflammation osteoarthritis (OA) and rheumatoid arthritis (RA). Results of analysis performed on an Asian OA group suggested that the IL-17A rs2275913 A allele [25][26][27] and IL-17F rs763780 G variant [26] increased susceptibility to knee OA.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Polymorphisms within Genes Coding for IL-17A and F and Their Receptor as Clinical Hallmarks in Ankylosing Spondylitis

Wielińska

Świerkot

Kolossa³

et al. 2021

Mediators of Inflammation

View full text Add to dashboard Cite

IL-17A and IL-17F together with their coreceptor (IL-17RA/RC) were reported to play a significant role in the pathogenesis of spondyloarthritis. The group of axial spondyloarthritis comprises ankylosing spondylitis (AS), a rheumatic disease characterized by chronic inflammation of the joints in the spine. This study is aimed at investigating IL-17A, IL-17F, IL-17RA, and IL-17RC polymorphisms as potential biomarkers of disease susceptibility, clinical parameters, and anti-TNF treatment outcome in a cohort of Polish ankylosing spondylitis patients. In total, 328 subjects, including 138 AS patients and 190 healthy volunteers, participated in the study. Genotyping of IL-17A rs2275913 (G/A), IL-17F rs763780 (A/G), IL-17RA rs4819554 (A/G), and IL-17RC rs708567 (G/A) was performed on real-time PCR instrument using LightSNiP assays. No significant differences were revealed in genotype and allele distribution between patients and controls despite the association of the IL-17RC rs708567 AA homozygosity with the earlier onset of the disease. Moreover, some relationships between IL-17F rs763780 and IL-17RA rs4819554 polymorphisms with clinical parameters related to the disease activity and anti-TNF treatment outcome were observed. IL-17F rs763780 G allele was found to be associated with high disease activity and BASDAI after 6 months and poor response to the treatment while higher VAS values were more common among IL-17RA rs4819554 G variant carriers. In conclusion, the IL-17F rs763780 polymorphism should be considered as a promising biomarker of disease activity and anti-TNF treatment outcome. The IL-17RA rs48419554 G allele may serve as a potential marker of disease severity in Polish AS patients.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The disease affects mostly men (ratio men to women is 2 to 1), those under thirty years of age, and with a strong genetic association linked to HLA-B27 [2]. Prevalence differs between geographical regions and ethnicity, reaching 0.23% in the general European population [3] and roughly 0.083% in Polish people [4].…”

Section: Introductionmentioning

confidence: 99%

Polymorphisms within Genes Coding for IL-17A and F and Their Receptor as Clinical Hallmarks in Ankylosing Spondylitis

Wielińska

Świerkot

Kolossa³

et al. 2021

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…The prevalence of AS is estimated at around 0.3-0.5% in Europe and 0.3-1.5% in the world (2) . The prevalence in the Polish population for 2008-2017 was approximately 0.1% (3) . The disease mainly affects young people and is more common in males.…”

Section: Introductionmentioning

confidence: 98%

“…The disease mainly affects young people and is more common in males. In Poland, the average male/female ratio for the incidence of AS in 2008-2017 was 1.33 (3) . AS aetiology is multifactorial and has not been yet completely recognised.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of TNF-α inhibitors in the treatment of ankylosing spondylitis

Elert-Kopeć¹,

Tłustochowicz²,

Bachta³

et al. 2021

Pediatr Med Rodz

Self Cite

View full text Add to dashboard Cite

Purpose: The study aimed to evaluate and compare the efficacy of TNF-α inhibitors in the treatment of ankylosing spondylitis in everyday medical practice. Materials and methods: We analysed the data of 106 patients with ankylosing spondylitis treated in 2012–2019 with TNF-α inhibitors (etanercept, adalimumab or golimumab) under the drug program of the National Health Fund. The observation period for each patient was 18 months. The disease activity was assessed at 3-month intervals on the basis of BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and ASDAS (Ankylosing Spondylitis Disease Activity Score). Results: The study covered 80 men and 26 women. The mean age of the patients was 37 years. The group receiving etanercept included 50 patients, adalimumab – 39 patients, and golimumab – 17 patients. Due to coexisting offaxial symptoms such as uveitis (n = 20/106) and peripheral arthritis (n = 39/106), some patients were simultaneously receiving classic disease-modifying antirheumatic drugs, i.e. methotrexate (n = 32/106), sulfasalazine (n = 8/106), cyclosporine (n = 5/106), and glucocorticosteroids (n = 14/106). All subgroups showed a significant clinical improvement in the form of a decrease in inflammatory markers and a decrease in disease activity after 3 months of treatment, increasing up to the 6th month. The biological drug was discontinued due to remission (according to BASDAI) in 20/48 patients taking etanercept and in 19/36 patients receiving adalimumab. The observation period following drug discontinuation for both groups was similar and lasted about 7 months. The remission time (according to BASDAI) without treatment was short; 3.55 ± 2.28 months for etanercept vs. 5.21 ± 2.53 months for adalimumab (p = 0.038). Conclusions: The inclusion of TNF-α inhibitors in patients with an unsatisfactory response to treatment with non-steroidal anti-inflammatory drugs resulted in a major reduction of disease activity. There was no statistically significant difference in treatment efficacy between individual TNF-α inhibitors, i.e. etanercept, adalimumab, and golimumab. The group treated with adalimumab was found with a trend towards longer-lasting remission after drug discontinuation, but it was short-lived and a return to treatment was necessary.

show abstract

“…While some studies suggest a SpA prevalence below 1% [ 7 – 9 ], it is thought that certain geographical regions can have a prevalence as high as 1.4% [ 10 ]. The discrepancies can be attributed to variations in the methodology and sample size, yet, it is widely recognized that the prevalence is significantly influenced by the underlying prevalence of the human leukocyte antigen (HLA)-B27 [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Diagnosis, monitoring, and management of axial spondyloarthritis

Zimba,

Kocyigit,

Korkosz

2024

Rheumatol Int

View full text Add to dashboard Cite

Axial spondyloarthritis (axSpA) is a chronic condition predominantly affecting the spine and sacroiliac joints. This article provides an in-depth overview of the current approaches to diagnosing, monitoring, and managing axSpA, including insights into developing terminology and diagnostic difficulties. A substantial portion of the debate focuses on the challenging diagnostic procedure, noting the difficulty of detecting axSpA early, particularly before the appearance of radiologic structural changes. Despite normal laboratory parameters, more than half of axSpA patients experience symptoms. X-ray and magnetic resonance imaging (MRI) are essential for evaluating structural damage and inflammation. MRI can be beneficial when there is no visible structural damage on X-ray as it can help unravel bone marrow edema (BME) as a sign of ongoing inflammation. The management covers both non-pharmacological and pharmacological approaches. Lifestyle modifications, physical activity, and patient education are essential components of the management. Pharmacological therapy, including nonsteroidal anti-inflammatory drugs (NSAIDs) and biologic disease-modifying anti-rheumatic drugs (bDMARDs), are explored, emphasizing individualized treatment. To effectively manage axSpA, a comprehensive and well-coordinated approach is necessary, emphasizing the significance of a multidisciplinary team. Telehealth applications play a growing role in axSpA management, notably in reducing diagnostic delays and facilitating remote monitoring. In conclusion, this article underlines diagnostic complexities and emphasizes the changing strategy of axSpA treatment. The nuanced understanding offered here is designed to guide clinicians, researchers, and healthcare providers toward a more comprehensive approach to axSpA diagnosis and care.

show abstract

Prevalence of axial spondyloarthritis in Poland

Cited by 6 publications

References 18 publications

Polymorphisms within Genes Coding for IL-17A and F and Their Receptor as Clinical Hallmarks in Ankylosing Spondylitis

Polymorphisms within Genes Coding for IL-17A and F and Their Receptor as Clinical Hallmarks in Ankylosing Spondylitis

Efficacy of TNF-α inhibitors in the treatment of ankylosing spondylitis

Diagnosis, monitoring, and management of axial spondyloarthritis

Contact Info

Product

Resources

About